MECHANISM OF ACTION

MECHANISM OF ACTION

Reblozyl addresses ineffective late-stage erythropoiesis by promoting erythroid maturation1-3

Reblozyl is a recombinant fusion protein that binds selected TGF-β superfamily ligands to reduce Smad 2/3 signaling, which is abnormally high in disease models characterized by ineffective erythropoiesis (ie, MDS and β-thalassemia).1-3

Reblozyl is a first-in-class erythroid maturation agent1

Reblozyl addresses ineffective late-stage erythropoiesis by promoting erythroid maturation1-3

Reblozyl is a first-in-class erythroid maturation agent1

Reblozyl is a recombinant fusion protein that binds selected TGF-β superfamily ligands to reduce Smad 2/3 signaling, which is abnormally high in disease models characterized by ineffective erythropoiesis (ie, MDS and β-thalassemia).1-3

References:

1. Reblozyl® (luspatercept) Summary of Product Characteristics (SmPC). Celgene 2020.

2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.

3. Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.  

 

This site is not intended for US or UK healthcare professionals.

The product has received European Medicines Agency approval. The registration status and approved product labels of Reblozyl may vary from country to country. The information on this website is not country-specific and may not be applicable to your country. For more information, please refer to your local Prescribing Information.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
This site is not intended for US or UK healthcare professionals. View the US site.
The information provided on this website is intended for use by a healthcare professional qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.
I am a European Healthcare Professional (UK excluded)
I am NOT a European Healthcare Professional
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See Section 4.8 in the EU Summary of Product Characteristics for more information. Before prescribing Reblozyl, please refer to the
EU Summary of Product Characteristics.